Clinical Trial Update: A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial of Galegenimab (FHTR2163) in geographic atrophy due to age-related macular degeneration was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy
• Macular Degeneration Age-related

Drugs mentioned

• Galegenimab (FHTR2163)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Degeneration, Age-Related, Geographic Atrophy | Phase 2 | Status: TERMINATED | Results posted: 2024-03-27